Fact CheckerSign in

NCT07440901Not yet recruiting

Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy

An Exploratory Study on the Remodeling of MHC-related Tumor Immune Microenvironment in Patients With Muscle-invasive Bladder Cancer After Neoadjuvant Therapy

Source: ClinicalTrials.gov · Last updated 27 Feb 2026

Brief summary (registry, in English)

In this study, the relevant biomarkers for predicting the efficacy of neoadjuvant therapy in patients with MIBC were further explored. Meanwhile, the dynamic molecular monitoring of neoadjuvant therapy in MIBC patients and the treatment guidance based on the MHC tumor immune microenvironment were also explored to select the treatment plan based on relevant biomarkers for subsequent immunotherapy in MIBC patients.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
30 (estimated)
First submitted
16 Sept 2025
Start date
1 Feb 2026
Primary completion date
15 May 2026
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT number
NCT07440901

What you commit to

  • Study type: Observational
  • Planned participants: 30
  • From 1 Feb 2026 to the primary completion date, 15 May 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Patients with previous malignant tumors were not eligible to participate in the study unless they had achieved complete remission for at least 5 years prior to enrollment and did not require additional treatment or did not require additional treatment during the study.
  • Combined with serious internal medical diseases including but not limited to: uncontrolled diabetes, active peptic ulcer, active bleeding, etc.

Other

  • Patients with insufficient communication, understanding and cooperation, or poor compliance, cannot be guaranteed to complete follow-up as required.

Who the study is looking for

  • Male or female, aged ≥18 years.
  • Expected survival ≥12 weeks.
  • Diagnosed by histopathology as muscle-invasive bladder urothelial carcinoma (MIBC) without upper urothelial carcinoma.
  • Clinical stage (cT2-T4a, N0-1, M0) and no distant metastasis as evaluated by imaging.
  • The subjects were assessed by urologists as tolerable and planned radical cystectomy.
  • ECOG Physical Condition 0-2.

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.